Before you sign up, get four answers in writing: whether the drug is an FDA-approved brand product or a compounded version, which pharmacy fills it, whether the monthly price changes as your dose goes up, and what screening and follow-up the clinician actually does. The answers sort good programs from storefronts faster than any review. FDA's own position, current as of October 2026, is that compounded GLP-1s should be used only when an approved drug can't meet a patient's medical needs.
Brand vs compounded: settle this first
Everything else, including price, pharmacy and paperwork, follows from which category you're buying.
- FDA-approved brand products for chronic weight management include injectable semaglutide (Wegovy), injectable tirzepatide (Zepbound), the Wegovy pill (oral semaglutide, approved December 2025) and orforglipron (Foundayo, approved in April 2026). Manufacturers now sell some of these directly to self-pay patients. Lilly, for example, launched Foundayo through LillyDirect.
- Compounded semaglutide or tirzepatide is made by a pharmacy, isn't FDA-approved, and has a much narrower legal footing now that the national shortages are over.
FDA's consumer page on unapproved GLP-1s spells out the risks. As of May 31, 2026, the agency had received 990 adverse event reports for compounded semaglutide and more than 730 for compounded tirzepatide. FDA notes these are likely underreported and that a report doesn't prove the drug caused the event. Some reports involved dosing errors, from patients measuring their own doses and from clinicians miscalculating. FDA also says salt forms like semaglutide sodium and semaglutide acetate have no known lawful basis for compounding, and that retatrutide and cagrilintide can't be used in compounding under federal law.
For how the molecules themselves compare, see our semaglutide vs tirzepatide vs retatrutide breakdown.
The four pricing models you'll run into
We don't print program prices; they change too often to be trustworthy in an article. What you can compare is structure.
| Model | How it works | What to ask |
|---|---|---|
| All-in subscription | One monthly fee covers the visit, the medication and shipping | Does the fee rise as the dose increases? What happens if I need a different drug? |
| Membership + medication | A clinical membership fee, with the drug billed separately | What does the membership alone include? Can I use my own pharmacy or insurance? |
| Per-fill | You pay per shipment, sometimes with a visit fee | Is there a minimum commitment? Are follow-ups extra? |
| Brand access + consult | The clinic prescribes; you buy brand through insurance or a manufacturer's self-pay channel | Will they handle prior authorization? Is the consult fee separate from the drug cost? |
Two traps show up across all four. First, dose-tiered pricing: the intro price often covers only the starting dose, and the cost climbs as you titrate up. Second, multi-month prepay: a discount for paying three or six months up front is only a deal if you can get a refund when the drug doesn't suit you. Pharmacies generally can't take dispensed medication back.
Screening and labs a real program should do
A good program screens out people who shouldn't take these drugs and watches for known problems. The Wegovy label gives a sense of what's worth monitoring:
- Thyroid cancer history. GLP-1 labels carry a boxed warning and a contraindication for people with a personal or family history of medullary thyroid carcinoma or MEN 2. You should be asked about this.
- Kidney function. The label reports acute kidney injury, often alongside GI side effects and dehydration, with higher risk in people with existing kidney impairment.
- Blood sugar medications. In people with type 2 diabetes, clinically significant low blood sugar was more common on Wegovy than placebo (6.2% vs 2.5%). The risk matters most if you also take insulin or a sulfonylurea.
- Gallbladder history. Gallstones were reported in 1.6% of adults on Wegovy vs 0.7% on placebo.
- Heart rate. Mean resting heart rate rose 1 to 4 beats per minute versus placebo.
Ask the program which labs it requires before the first prescription, whether it accepts recent results from your own doctor, and when it rechecks. If the answer is "none," that tells you how the program is run.
The men-specific question: muscle
For men who train, the biggest practical issue is what kind of weight comes off. In the STEP 1 trial's body-composition substudy, roughly 38 to 39% of the weight lost on semaglutide was classified as lean mass on DXA. Some of that is water and organ mass rather than muscle, but it's why resistance training and protein matter more on a GLP-1, not less. A program worth paying for will at least ask about your training and protein intake. We go deeper in the muscle-loss problem.
Pharmacy questions to ask before you pay
- Is my prescription for a brand product or a compounded one?
- If compounded: which pharmacy, is it 503A or a registered 503B facility, and is it licensed in my state?
- Is the active ingredient the same base form as the approved drug, or a salt form such as semaglutide sodium or acetate?
- Does the product come with clear dosing instructions from the prescriber and a way to measure doses accurately?
- Does the label show the pharmacy name, address and a beyond-use date?
- Who do I call about a side effect, and how fast does a clinician respond?
Our 503A vs 503B explainer covers what those pharmacy categories mean, and the 12-point clinic checklist covers the clinic side.
FDA lists these red flags for online GLP-1 sellers: deep discounts, no required doctor screening, and misspelled labels or wrong pharmacy addresses. Add one more: anything labeled "for research purposes" or "not for human consumption" that comes with dosing instructions. FDA has issued warning letters to companies selling GLP-1s that way.
Telehealth programs we link to
Both of these put the prescribing decision with a licensed clinician. Use the questions above with either one:
Dosing for GLP-1 medications is set by the prescribing clinician. See our medical disclaimer. For the bigger picture on GLP-1s and men, read the complete GLP-1 guide for men.
Severe abdominal pain that spreads to the back, persistent vomiting, signs of dehydration, or pain in the upper right abdomen with fever need prompt in-person care. Don't wait for a portal reply.
Sources
- FDA, FDA's concerns with unapproved GLP-1 drugs used for weight loss (current as of October 1, 2026).
- Wegovy (semaglutide injection) prescribing information, adverse reactions section, via MedLibrary label text.
- Healio, FDA approves orforglipron, an oral GLP-1 for adults with obesity (April 1, 2026).
- Wilding JPH et al., Once-weekly semaglutide in adults with overweight or obesity (STEP 1), N Engl J Med 2021; lean-mass share as summarized by Barbell Medicine.
Frequently Asked
No. Compounded semaglutide is made by a pharmacy and is not FDA-approved, so it has not been reviewed for safety, effectiveness or quality the way Wegovy has. FDA says compounded GLP-1s should be used only when an approved drug cannot meet a patient's medical needs.
Many programs price by dose. The introductory price often covers only the starting dose, and the cost rises as the dose is increased. Ask for the price at each dose level before you sign up.
Ask the program directly. Reasonable screening covers thyroid cancer history, kidney function, diabetes medications, and gallbladder history, because the Wegovy label lists risks in each of those areas. A program that requires no screening at all is a red flag by FDA's own description.
Get the pharmacy's name before you pay, confirm its license with your state board of pharmacy, ask whether it is a 503A pharmacy or a registered 503B outsourcing facility, and check that the label shows the pharmacy's name, address and a beyond-use date.
Some of the weight lost is lean mass. In the STEP 1 body-composition substudy, about 38 to 39 percent of the weight lost on semaglutide was classified as lean mass on DXA, which is why resistance training and adequate protein matter during treatment.